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Abstract
Purpose of Review This review aims to summarize and discuss the recent findings in the field of using HDL mimetics for the
treatment of patients with coronary artery disease.
Recent Findings Following the largely disappointing results with the cholesteryl ester transfer protein inhibitors, focus moved to
HDL functionality rather than absolute HDL cholesterol values. A number of HDL/apoA-I mimicking molecules were devel-
oped, aiming to enhance reverse cholesterol transport that has been associated with an atheroprotective effect. Three HDL
mimetics have made the step from bench-testing to clinical trials in humans and are discussed here: apoA-I Milano, CSL-112,
and CER-001. Unfortunately, with the exception of CSL-112 where the results of the clinical trial are not yet known, none of the
agents was able to demonstrate a clinical benefit.
Summary HDLmimetics have failed to date to prove a beneficial effect in clinical practice. Reverse cholesterol transport remains
a challenging therapeutic pathway to be explored.
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Abbreviations
ABCA1 ATP binding cassette transporter A1
ABCG1 ATP binding cassette transporter G1
ACS Acute coronary syndrome
apoA-I Apolipoprotein A-I
apoB Apolipoprotein B
apoE Apolipoprotein E
CAD Coronary artery disease
CETP Cholesteryl ester transfer protein
FHA Familial hypoalphalipoproteinemia
HDL High-density lipoprotein
IVUS Intravascular ultrasonography
LCAT Lecithin-cholesterol acyltransferase
LDL Low-density lipoprotein
MRI Magnetic resonance imaging
mRNA Messenger RNA
QCA Quantitative coronary angiography
sdLDL Small dense LDL
SR-BI Scavenger receptor BI
Introduction
Observational studies in multiple populations indicate a con-
tinuous positive relationship among the prevalence of coro-
nary artery disease (CAD) and the blood LDL cholesterol
levels that extend well below the ranges seen in Western pop-
ulations, without any definite threshold below which a lower
cholesterol concentration is not associated with a lower risk
[1, 2]. Therefore, current practice guidelines concerning high-
risk populations are focusing on achieving very low levels of
LDL cholesterol, mainly through the systematic use of potent
statins. However, despite the efficiency of established thera-
pies, the residual burden of disease remains substantial [3].
Since its discovery by Miller and Miller in 1975 [4], HDL
has been associated with a potential protective effect against
atherosclerosis. HDL concentrations higher than 75 mg/dl
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(1.9 mmol/l) were associated with prolonged life (longevity
syndromes) and relative freedom from CAD [5]. In the
Framingham Study, the risk of CAD was shown to increase
sharply as HDL levels fell progressively below the 40 mg/dl
(1.04 mmol/l) [6]. The publication of the Helsinki Heart Study
in 1987 [7], where a simultaneous 11% increase in HDL and
reduction in LDL levels during gemfibrozil therapy were ac-
companied by a 34% reduction in myocardial infarction rates,
raised for the first time the issue of whether efforts to increase
HDL levels should be undertaken in patients with CAD and/or
dyslipidemia.
Use of HDL as a Therapeutic Target
Despite the substantial body of evidence from classical epide-
miological association studies, HDL cholesterol raising has
not been proven to actively reduce cardiovascular event risk
or affect the development of atherosclerosis [8]. The argument
for lack of causality (for HDL cholesterol) comes from
Mendelian randomization analyses on the one hand and the
difficulty in demonstrating improved outcomes with therapies
that raise HDL cholesterol on the other; therapeutic interven-
tions such as niacin and cholesteryl ester transfer protein
(CETP) inhibitors increase HDL cholesterol in patients treated
with statins but have repeatedly failed to reduce cardiovascu-
lar events with the sole exception of anacetrapib in the
REVEAL study, where, however, the beneficial effect was
not clearly associated to the rise of HDL alone [9, 10].
This discrepancy among the results of the initial clinical
trials on the one hand and the pre-clinical data demonstrating
atheroprotective properties of HDL on the other shifted focus
towards the functional properties of HDL and in particular the
stimulation of the reverse cholesterol transport schematically
presented in Fig. 1 [11]. We can roughly identify three stages
in the reverse cholesterol transport process: (1) cholesterol
efflux, where HDL/apolipoprotein A-I (apoA-I; the major
protein component of the HDL particles) remove excess cho-
lesterol from cells; (2) lipoprotein remodeling, where HDL
undergoes structural modifications with possible impact on
its function; and (3) hepatic lipid uptake, where HDL releases
cholesterol to the liver, for the final excretion into bile and
feces. The development of methods capable of measuring
cholesterol efflux capacity gave us a tool where the functional
properties of HDL could be measured. It has been demonstrat-
ed that sera with similar HDL or apoA-I levels may differ in
their ability to promote macrophage efflux, because of differ-
ences in the concentration of pre-β HDL [12]. Furthermore,
cholesterol efflux capacity proved to be a strong predictor for
cardiovascular events, independent of the actual HDL levels
[13, 14]. These scientific data reinforced our interest of using
HDL as a therapeutic target, aiming however for functional
HDL particles/HDL flux rather than simply raising the cho-
lesterol content of the HDL fraction.
Apolipoprotein A-I would represent a promising target.
Evidence from both animal and human studies [15–17] sug-
gests an important role of apoA-I in many of the anti-
atherogenic properties attributed to HDL. Several therapies
imitating apoA-I function have been tested, including admin-
istration of full-length apoA-I, mutated variants of apoA-I,
and apoA-I mimetic peptides.
ApoA1 Mimetic Peptides
Apolipoprotein A-I consists of 243 amino acids. Its secondary
structure resembles 10 amphipathic α-helices that seem to be
important for its efficient interaction with lipids. Over the last
25 years, multiple peptides resembling the amphipathic heli-
ces in apoA-I have been engineered and tested as therapeutic
agents, mostly in vitro as well as in the lab, in studies with
rodents. These agents and the corresponding studies are well
summarized in the review article of Stoekenbroek et al. [18••].
The in vitro properties of the engineered agents as well as the
main findings of the studies performed are summarized in
Table 1. To the moment, none of these apoA-I mimetic pep-
tides have been used in a clinical trial in humans.
ApoA-I-Based Infusion Therapy and Clinical Trials
in Humans
Based on animal models where apoA-I overexpression and
infusion inhibit plaque formation, it was hypothesized that
infusion of apoA-I containing particles, such as lipid-poor
pre-β HDL, would also have beneficial effects on plaque sta-
bilization and atherosclerosis regression. As early as in 1990,
Badimon et al. [26••] demonstrated that treatment of rabbits,
who were fed with an atherogenic diet for 60 days in order to
induce atherosclerotic lesions, with high-density/very high-
density lipoprotein infusions obtained by ultracentrifugation
did not only inhibit plaque formation but also reduced the
extent of preexisting lesions. Miyazaki et al. [27] could repli-
cate the results of Badimon, treating the rabbits with purified
apoA-I. However, it should be noted that the atherosclerotic
lesions in rabbits only partly resemble human atherosclerosis.
Therefore, testing of these compounds in patients is absolutely
necessary in order to determine the (magnitude of) beneficial
effects.
In the last few years, three infusible HDL mimetics have
made the step from bench testing to clinical trials in humans
and will be further discussed here: apoA-I Milano, CSL-112,
and CER-001.
i. apoA-I Milano. This is a naturally occurring mutation of
apolipoprotein A-I, originally documented in a small vil-
lage in Italy. Carriers of this mutation are characterized by
an exceptionally low prevalence of cardiovascular disease
despite decreased HDL cholesterol and apoA-I levels [28,
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29]. Compared to native apoA-I, apoA-I Milano has been
shown to induce more ATP-binding cassette transporter
A1 (ABCA1) mediated cholesterol efflux and to exert su-
perior anti-inflammatory and plaque stabilizing properties
Fig. 1 The reverse cholesterol transport pathway. Cholesterol-rich
lipoproteins are taken up by macrophages resulting in foam cell
formation. From macrophages, efflux of cholesterol follows three
pathways: (1) via ABCA1, received by lipid-poor apoA-I/pre-β HDL;
(2) via ABCG1, received by more mature spherical HDL particles; and
(3) SR-BI mediated or aqueous diffusion. Within HDL, cholesterol is
esterified by LCAT, making space on the HDL surface for the uptake of
additional free cholesterol. Subsequently, HDL is absorbed by the liver;
cholesterol is de-esterified and secreted into the bile. In humans, CETP
creates some short of “shunt” among the forward and the reverse
cholesterol transport pathways. Therefore, hepatic absorption of apoB
containing lipoproteins can also contribute in a way in the reverse
cholesterol transport pathway. Finally, the rate of cholesterol absorption
from the intestinal lumen has an impact on the amount of foam cell-
derived cholesterol that is finally excreted from the body
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[30]. These observations have led to the engineering of
formulations containing recombinant apoA-I Milano com-
plexed with phospholipids. In a phase II clinical trial, in a
small group of patients following an acute coronary syn-
drome (ACS), administration of such a molecule (ETC-
216, Esperion Therapeutics) produced significant regres-
sion of coronary atherosclerosis as measured by intravas-
cular ultrasonography (IVUS) [31]. The findings sug-
gested a potential novel strategy for the management of
patients with ACS, where the infusion of an agent the first
few weeks or months following an acute event would
stimulate reverse-cholesterol transport while ongoing ther-
apy with conventional lipid-modulating agents would pro-
vide long-term clinical benefits. However, serious side ef-
fects prevented further evaluation of this formulation.
Following optimization of the manufacturing process, a
newer formulation (not inducing adverse immunostimulation
like ETC-216 [32]) called MDCO-216 (The Medicines
Company) was tested in a double-blind, randomized, place-
bo-controlled, multicenter trial (MILANO-PILOT,
NCT02678923) with 122 post ACS patients on optimal con-
ventional medical treatment. Following five weekly MDCO-
216 infusions, both primary (percent atheroma volume) and
secondary efficacy parameters (normalized total atheroma
volume and atheroma volume in the most diseased segment)
did not differ significantly among the treated group and the
control group. The authors conclude that apoA-IMilano failed
to demonstrate (on IVUS) incremental regression of coronary
atherosclerosis, among patients with a history of ACS and
documented angiographic coronary disease, in the setting of
contemporary statin therapy (results presented at the
American Heart Association Congress, New Orleans 2016).
Further development of MDCO-216 has now ceased.
ii. CSL-112. Produced by the Commonwealth Serum
Laboratories, this is a reconstituted HDL particle,
consisting of native apoA-I and phospholipids. A prede-
cessor compound, CSL-111, was tested in the ERASE
trial, where IVUS studies on post ACS patients receiving
weekly infusions, failed after 4 weeks to lead to signifi-
cant reductions in atheroma volume or plaque volume
compared with placebo but did result in statistically sig-
nificant improvement in the plaque characterization index
and coronary score on quantitative coronary angiography
(QCA), thereby suggesting a therapeutic potential, ac-
cording to the authors [33]. However, administration of
high doses of CSL-111 was also associated with hepato-
toxicity leading to the development of CSL-112. The later
compound, which appeared to be safe in two phase I
clinical trials in healthy individuals, was associated with
a dose-dependent increase in apoA-I which remained
above baseline for approximately 3 days after infusion.
A rapid 36-fold increase in pre-β HDL levels was also
noted, which was accompanied by increased ABCA1-
mediated cholesterol efflux (maximum increase 270%
compared to baseline). Multiple infusions of CSL-112
were well tolerated with no evidence of major organ tox-
icity or immunogenicity [34]. In the AEGIS-I trial that
followed, a large 2b clinical trial including 1258 patients
with a recent acute myocardial infarction, the aim was to
determine the safety, tolerability, pharmacokinetics, and
pharmacodynamics of CSL112. The authors of the study
concluded that four weekly infusions of CSL112 are fea-
sible, well tolerated, and not associated with any signifi-
cant alterations in liver or kidney function [35].
Moreover, the study confirmed the ability of CSL-112
to acutely enhance cholesterol efflux. However, the po-
tential benefit of CSL112 in reducing major adverse
Table 1 ApoA1 mimetic peptides
ApoA1-
mimetic
peptide
Method of
administration
In vitro properties In vivo results (mice) Tested in humans
4F Oral/parenteral • Anti-inflammatory
• Anti-oxidant
• Conflicting results on HDL-mediated protection against
LDL induced monocyte chemotaxis [19, 20]
No, development
stopped
6F Oral • Anti-inflammatory
• Anti-oxidant
• Reduction of inflammatory biomarkers
• Reduction of aortic lesion area [21]
No studies yet
FX-5A Parenteral • Induces cholesterol efflux both
through ABCA1 and ABCG1
• Increased cholesterol efflux
• Anti-inflammatory properties
• Anti-oxidant properties [22, 23]
Not studies yet,
possible in the
future
ATI-5261 Parenteral • ABCA1-mediated cholesterol
efflux
• Increased reverse cholesterol transport [24] No studies
ETC-642 Parenteral • Reduction of pro-inflammatory
oxidized LDL
• Reduction of sdLDL
• Increase of anti-atherogenic pre-β
HDL
• Inhibition of atherosclerotic plaque formation [25] No studies
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cardiovascular events in this group of high-risk patients
(following an acute coronary syndrome) still remains to
be shown in the large phase III AEGIS-II study
(NCT03473223) that is currently recruiting patients and
is expected to be concluded in 2022.
iii. CER-001. CER-001 (Cerenis Therapeutics, France) is a
negatively charged lipoprotein complex mimicking dis-
coidal pre-β HDL, consisting of recombinant human
apoA-I and a combination of two naturally occurring
phospho l ip ids , d iphospha t idy lg lycero l , and
sphingomyelin. Preliminary studies showed that, follow-
ing iv administration, CER-001 can rapidly mobilize
large amounts of cholesterol into the HDL fraction. The
CHI-SQUARE study [36] was designed to assess the
safety and efficacy of CER-001 in the clinical setting.
A total of 507 patients with a clinical indication for cor-
onary angiography were included; IVUS and QCAwere
performed to assess coronary atherosclerosis at baseline
and 3 weeks after the last study infusion. Patients were
randomized to receive six weekly infusions of placebo, 3,
6, or 12 mg/kg CER-001. Despite the dose-related in-
crease in cholesterol mobilization observed (estimated
by the increase in plasma cholesterol after CER-001 in-
fusion), neither IVUS nor QCAwere indicative of reduc-
tion of coronary atherosclerosis in the treated groups
when compared to placebo. However, a post hoc analysis
demonstrated that in patients with a baseline percent ath-
eroma volumemore than 30%, infusions of CER-001 at a
dose of 3 mg/kg induced the greatest atheroma regres-
sion, while higher concentrations of CER-001 did not
differ from the placebo [37]. The underlying mechanism
for this observation seems to be the strong (50%) down-
regulation of the ABCA1 transporter mRNA and mem-
brane protein expression at higher doses of CER-001,
therefore attenuating the active, regulated, and energy-
dependent ABCA1 transporter-mediated cellular sterol
efflux, as shown by Tardy et al. with their in vivo model
with apoE−/−mice [38]. It seems that high doses of HDL
and CER-001 are less effective in slowing progression of
atherosclerotic plaque, following a U-shaped dose-
response curve. Tardy et al. concluded that at a dose of
2–5 mg/kg CER-001 could achieve maximal efficacy in
removing cholesterol from lipid-laden macrophages in
the atherosclerotic plaque while minimizing downregu-
lation of ABCA1 expression.
Based on these observations, the effect of a 3mg/kgCER-001
dose was evaluated in the CARAT study (NCT02484378) [39].
A total of 301 patients with status post ACS and a baseline
percent atheroma volume > 30% in proximal 10 mm in a target
vessel were randomized to receive 9 weeks of treatment with
either low dose of CER-001 or placebo. Although the results of
the study have only been presented and not yet officially
published, treatment with CER-001 did not produce a significant
effect on either of the primary efficacy endpoints (i.e., percent
atheroma volume and total atheroma volume, as assessed with
IVUS) when compared to placebo. Therefore, we can conclude
that in the setting of post ACS and with the background of
contemporary treatment, treatment with CER-001 does not rep-
resent a promising strategy. Whether CER-001 could be used in
other clinical settings remains still to be examined.
One such scena r i o i s pa t i en t s w i th f ami l i a l
hypoalphalipoproteinemia (FHA) as well as homozygous fa-
milial hypercholesterolemia. In two small studies with patients
of these groups, repeated (over a period of 6 months) infusions
of CER-001 resulted in regression of atherosclerosis, as it was
assessed with 3-T magnetic resonance imaging (MRI) scans
of the carotid arteries at baseline and at the end of the study
[40, 41]. There is currently a phase III clinical study running
(still recruiting patients), using 3-T MRI scans of the carotid
artery to evaluate the effect of CER-001 infusions on athero-
sclerosis in FHA patients (TANGO trial, NCT02697136).
Discussion
The therapeutic potential of targeting HDL remains to date
obscure. While population studies consistently demonstrate
an inverse relationship between HDL cholesterol and cardio-
vascular events, multiple clinical trials over the course of the
last decade have failed to demonstrate any benefit from raising
HDL or infusing HDL on regression of coronary atheroscle-
rosis or on clinical events.
The large randomized controlled trials with the cholesterol
ester transfer protein inhibitors produced rather disappointing
results [42, 43] with the exception of anacetrapib [10].
Anacetrapib, however, is a potent agent with additional proper-
ties such as reducing levels of apolipoprotein B containing ath-
erogenic lipoproteins; therefore, it remains unclear whether the
benefit seen should be attributed to the rise of HDL cholesterol
levels or the 18% relative reduction of the non-HDL cholesterol.
Moreover, extended follow-up of a subset of DEFINE partici-
pants showed that it has a long terminal half-life such that low
levels of anacetrapib (about 8% of apparent steady-state on-treat-
ment trough exposures and 2% of apparent steady-state peak
concentrations) were detected in blood 2.5 to 4 years after cessa-
tion of therapy [44]. Therefore, its long-term safety is question-
able and it will not reach the market.
The shift to HDL mimetics as a potential therapeutic target
was guided by the observation (mentioned earlier in this doc-
ument) that cholesterol efflux capacity is a strong predictor for
cardiovascular events, independent of the actual HDL levels
[13, 14]. Interestingly, studies have shown that disruption in
the cholesterol homeostasis/cholesterol efflux pathways or
prolonged exposure to a hypercholesterolemic environment
can influence myelopoiesis [45]. More specifically,
Curr Cardiol Rep (2018) 20: 66 Page 5 of 8 66
hematopoietic stem and multipotential progenitor cells in the
bone marrow and other medullary organs may be affected,
leading to monocytosis. These monocytes, once they enter
the atherosclerotic plaque, may possess a pre-programmed
ability to induce inflammation. The physiology of the athero-
sclerosis is therefore so complex that the traditional cardio-
centric view of physicians regarding ischemic heart disease,
i.e., plaques grow in arteries until they block blood flow, caus-
ing acute coronary and other ischemic syndromes, is now
considered naive. Recent research reveals complex inflamma-
tory signaling networks that link the brain, autonomic nervous
system, bone marrow, and spleen to the atherosclerotic plaque
or even the infarcting myocardium [46]. Under this perspec-
tive, therapeutic options aiming to enhance cholesterol efflux
pathways in myeloid progenitors, ultimately attenuating leu-
kocyte production, seems a reasonable choice.
Therefore, it is surprising that despite the promising
theoretical background and while both apoA-I Milano
and CER-001 infusions produced predictable increases
in cholesterol efflux capacity, they failed to translate in a
favorable effect on regression of coronary atherosclerosis/
coronary plaque burden, in the setting of randomized,
placebo-controlled clinical trials in humans. Like the
HDL cholesterol levels in the case of CETP inhibitors
before, cholesterol efflux capacity induced by the current-
ly available agents (and in the setting they have been
used) appears to be an inadequate surrogate for therapeu-
tic use. However, the role of reverse cholesterol transport
in counteracting the pathogenic events leading to the for-
mation and development of atheroma remains a valid hy-
pothesis, as recent studies suggest. Impaired reverse cho-
lesterol transport due to reduced hepatic scavenger recep-
tor BI (SR-BI) function leads to increased risk of CAD
despite elevation in HDL cholesterol levels [47•]. Whether
upregulation or enhancement of SR-BI could be a novel
therapeutic approach to reducing CAD risk in the general
population still remains to be proven.
It should be noted that all these elegant and well con-
ducted clinical trials (despite the negative results) have
been performed in the setting of ACS. The rational is that
these patients require aggressive treatment and that they
would benefit the most from an intervention. However,
over the last 10–15 years, the development and wide
adoption of newer-generation potent statins have greatly
improved our therapeutic result and the prognosis of these
patients, probably leaving little space to HDL mimetic
agents to be of benefit. Moreover, there is growing evi-
dence that HDL biology has to do more with the achieve-
ment of a steady-state, slow, and continuous flux, rather
than absolute levels of HDL cholesterol. Whether these
agents would be more effective when administered over
a longer period of time and in the setting of stable coro-
nary artery disease, where background therapy remains
largely unchanged and therefore atherogenic lipoproteins
and inflammatory markers are not significantly affected, is
unknown. Of note, infusion therapies are way too imprac-
tical for long term use.
Another issue to consider is whether the primary efficacy
end points chosen in the clinical studies are the most appro-
priate ones. Pre-clinical bench models suggest that HDL in-
duces remodeling of the atherosclerotic plaque, in terms of
cellular composition, to a more stable-appearing phenotype
prior to atheroma size reduction [48]. However, there is cur-
rently no validated imaging mobility, translating into clinical
outcomes, that can assess such a process with sufficient pre-
cision. On the contrary, in the case of atherosclerosis imaging
with IVUS, studies have associated plaque burden and its
progression to adverse cardiovascular outcomes [49], there-
fore supporting its use as a surrogate in the evaluation of novel
anti-atherosclerotic therapies. It seems unlikely that choosing
a different approach in evaluating HDL mimetics would have
provided a compelling reason to advance in clinical develop-
ment of these agents.
Conclusion
Recent studies using HDL mimetics in patients with acute
coronary syndrome have failed to demonstrate a favorable
effect on coronary atherosclerosis, therefore suggesting that
this is not a promising strategy in this particular clinical set-
ting. On the other hand, there is sufficient evidence that re-
verse cholesterol transport is a valid pathway to reduce the risk
for CAD. Whether HDL-focused therapy can impact plaque
or clinical events in the setting of contemporary therapy re-
mains to be determined, although with each disappointing
study result, the challenge increases.
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